Epstein-Barr virus peptides derived from latent cycle proteins alter NKG2A + NK cell effector function

Area of Science:

• Immunology
• Virology
• Molecular Biology

Background:

• Natural killer (NK) cells are crucial for controlling viral infections.
• NK cell activity is regulated by inhibitory receptors interacting with human leukocyte antigen (HLA) ligands.
• NKG2A/CD94 is an inhibitory receptor on NK cells that recognizes HLA-E.

Purpose of the Study:

• To investigate the mechanism by which NK cells recognize Epstein-Barr virus (EBV)-infected B cells.
• To determine if peptides from EBV latent proteins interact with NKG2A/CD94 and HLA-E.
• To explore the impact of EBV latent protein variations on NK cell responses.

Main Methods:

• Analysis of peptides derived from seven EBV latent proteins.
• Functional assays to assess peptide binding to HLA-E.
• Investigation of the interaction between EBV peptides, HLA-E, and the NKG2A receptor.
• DNA sequencing of the EBV latent protein LMP1 in 79 subjects.

Main Results:

• EBV-derived peptides were found to bind to HLA-E.
• These EBV peptides blocked the inhibitory function of NKG2A, leading to NK cell activation.
• Sequence variations in the EBV latent protein LMP1 were identified, correlating with altered NK cell responses.
• Evidence suggests EBV peptides can evade NKG2A recognition mediated by HLA-E.

Conclusions:

• Peptides from EBV latent proteins can interfere with the NKG2A/HLA-E interaction, promoting NK cell activation.
• This mechanism may allow EBV to evade NK cell surveillance.
• Genetic variations in EBV's LMP1 protein influence the host's NK cell-mediated immune response to the virus.